- CSL +1.76%
Carlisle Companies Incorporated (NYSE:CSL) Q1 2024 Earnings Call Transcript
Yahoo Finance · 6 days ago
Open | 402.00 |
High | 408.08 |
Low | 401.96 |
Mkt Cap | 19.3B |
P/E (TTM) | 25.12 |
Div & Yield | 3.40 & 0.85% |
Prev. Close | 398.47 |
52 Wk. Low | 205.10 |
52 Wk. High | 415.00 |
Related stocks
Australian biotechnology company
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 1.1B | 22.80% ▲ |
Net Income | 192.3M | 89.10% ▲ |
Diluted EPS | 3.72 | 102.10% ▲ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $5.84 | - |
Q1 2024 | $2.82 | $3.72 |
Q4 2023 | $3.55 | $4.17 |
S&P 500^GSPC | 5,180.74+52.95 (+1.03%) |
Dow 30^DJI | 38,852.27+176.59 (+0.46%) |
Nasdaq^IXIC | 16,349.25+192.92 (+1.19%) |
25.21+8.06% | |
3.0500+9.52% | |
116.47+2.47% |